Key Highlights
- Holoclara raises $16M in Series A financing.
- Led by BOLD Capital Partners, with participation from Horizons Ventures and others.
- Funding will progress development of orally available therapeutics.
- Peter Barton Hutt appointed to the Board of Directors.
- Advancing discovery engine for worm-derived therapeutic molecules.
Source: Business Wire
Notable Quotes
- “With our world-class team and leading investors, we are taking matters into our own hands to usher in a new era of medicines inspired by nature that can transform the lives of millions of people.” — Andrea Choe, M.D., Ph.D., CEO at Holoclara
- “Holoclara’s ‘against the grain’ approach of seeking inspiration from worms intrigued the BOLD Capital team from the very start. By focusing on a particular worm species that had co-evolved with humans over hundreds of thousands of years as a gut-resident parasite.” — Neal Bhadkamkar, Ph.D., General Partner at BOLD Capital Partners
- “I’m pleased to advise Holoclara as the company moves its groundbreaking science harnessing worm biology closer to the clinic and into the hands of countless patients suffering from allergic and autoimmune diseases today.” — Peter Barton Hutt, Senior Counsel at Covington & Burling LLP
SoHC's Take
Holoclara’s innovative approach of leveraging worm-derived molecules for therapeutic purposes marks a significant breakthrough in biotechnology. By securing substantial Series A financing, the company is well-positioned to advance its unique therapies into clinical trials. The appointment of seasoned industry veterans like Peter Barton Hutt further strengthens their leadership team. Holoclara’s progress not only underscores the potential of nature-inspired solutions but also promises transformative treatments for chronic and often debilitating conditions like allergies and autoimmune disorders. This milestone is a promising step toward addressing unmet clinical needs with groundbreaking scientific advancements.
